NEW YORK (GenomeWeb) – Metabolon announced today that it has signed a deal to commercialize its Quantose IR insulin resistance test in 30 international markets with European clinical laboratory network Synlab.
Quantose IR is a blood-based test uses insulin and three non-glycemic biomarkers to assess the risk of a patient developing prediabetes. Under the terms of the arrangement, Synlab will introduce the test first in Spain and then in other markets throughout Europe, Latin America, and the Middle East during 2016.
Additional terms of the deal were not disclosed.
"This collaboration between our two companies is an important step toward making Quantose IR and future precision medicine and diagnostics products widely available across the globe," Metabolon CEO John Ryals said in a statement.
In late 2014, Durham, North Carolina-based Metabolon signed an agreement allowing Metdia Biotech to commercialize Quantose IR, as well as the impaired glucose tolerance test Quantose IGT, in 14 European countries including Spain. However, that partnership ended in early 2015, according to a company official.